<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">Liver metastasis</z:e> is the predominant cause of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>)-related mortality in developed countries </plain></SENT>
<SENT sid="1" pm="."><plain>Carcinoembryonic antigen-related cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule 1 (CEACAM1) is a cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule with reduced expression in early phases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> development and thus functions as a <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> inhibitor </plain></SENT>
<SENT sid="2" pm="."><plain>However, CEACAM1 is upregulated in metastatic <z:hpo ids='HP_0003003'>colon cancer</z:hpo>, suggesting a bimodal role in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> progression </plain></SENT>
<SENT sid="3" pm="."><plain>To investigate the role of this protein in the host metastatic environment, Ceacam1(-/-) mice were injected intrasplenically with metastatic MC38 mouse <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
<SENT sid="4" pm="."><plain>A significant reduction in metastatic burden was observed in Ceacam1(-/-) compared with <z:mp ids='MP_0002169'>wild-type</z:mp> (WT) livers </plain></SENT>
<SENT sid="5" pm="."><plain>Intravital microscopy showed decreased early survival of MC38 cells in Ceacam1(-/-) endothelial environment </plain></SENT>
<SENT sid="6" pm="."><plain>Metastatic cell proliferation within the Ceacam1(-/-) livers was also diminished </plain></SENT>
<SENT sid="7" pm="."><plain>Bone marrow-derived cell recruitment, attenuation of immune infiltrates and diminished CCL2, CCL3 and CCL5 chemokine production participated in the reduced Ceacam1(-/-) metastatic phenotype </plain></SENT>
<SENT sid="8" pm="."><plain>Transplantations of WT bone marrow (BM) into Ceacam1(-/-) mice fully rescued metastatic development, whereas Ceacam1(-/-) BM transfer into WT mice showed reduced metastatic burden </plain></SENT>
<SENT sid="9" pm="."><plain>Chimeric immune cell profiling revealed diminished recruitment of CD11b(+)Gr1(+) myeloid-derived suppressor cells (MDSCs) to Ceacam1(-/-) metastatic livers and adoptive transfer of MDSCs confirmed the involvement of these immune cells in reduction of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>CEACAM1 may represent a novel metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> target for treatment </plain></SENT>
</text></document>